<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00006380</url>
  </required_header>
  <id_info>
    <org_study_id>99-061</org_study_id>
    <secondary_id>CDR0000068254</secondary_id>
    <secondary_id>NCI-G00-1870</secondary_id>
    <nct_id>NCT00006380</nct_id>
  </id_info>
  <brief_title>Monoclonal Antibody Therapy in Treating Patients With Prostate Cancer</brief_title>
  <official_title>Phase I Evaluation of 131I-J591 Murine Monoclonal Antibody in Patients With Progressive Androgen-Independent Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver&#xD;
      tumor-killing substances to them without harming normal cells.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of monoclonal antibody therapy in treating&#xD;
      patients who have prostate cancer that no longer responds to antiandrogen therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine the biodistribution and normal organ dosimetry of iodine I 131&#xD;
      monoclonal antibody muJ591 in patients with progressive androgen independent prostate cancer.&#xD;
      II. Determine the safety of this drug in these patients. III. Determine the pharmacokinetics&#xD;
      of this drug in these patients. IV. Determine the human antimouse antibody response in these&#xD;
      patients to this drug. V. Determine the antitumor effects of this drug in these patients.&#xD;
&#xD;
      OUTLINE: This is a dose escalation study of iodine I 131 monoclonal antibody muJ591&#xD;
      (131I-J591). Patients receive unlabeled monoclonal antibody muJ591 IV over 1 hour followed by&#xD;
      131I-J591 IV over 1 hour. Cohorts of 3-6 patients receive escalating doses of 131I-J591&#xD;
      (radioactivity is escalated, monoclonal antibody dose is fixed) until the maximum tolerated&#xD;
      dose (MTD) is determined. The MTD is defined as the dose at which 2 of 3 or 6 patients&#xD;
      experience dose limiting toxicity. Patients are followed at weeks 3, 4, 6, 8, 9, and 12, and&#xD;
      then every 6 months until month 21.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 3-24 patients will be accrued for this study over 12 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2000</start_date>
  <completion_date type="Actual">March 2002</completion_date>
  <primary_completion_date type="Actual">March 2002</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Prostate Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>monoclonal antibody muJ591</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>iodine I 131 monoclonal antibody muJ591</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Histologically confirmed androgen independent prostate cancer that&#xD;
        is progressing under castrate levels of testosterone Progression documented in one of the&#xD;
        following ways: A minimum of 3 rising PSA values from baseline obtained 1 week or more&#xD;
        apart or 2 measurements 2 weeks or more apart New osseous lesions on bone scan Greater than&#xD;
        25% increase in bidimensionally measurable soft tissue disease, or the appearance of new&#xD;
        sites of disease Patients on an antiandrogen must have shown progression off of the&#xD;
        antiandrogen prior to study Testosterone no greater than 50 ng/mL No residual proctitis&#xD;
        following radiotherapy No active CNS or epidural primary tumor or metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 60-100% Life&#xD;
        expectancy: Not specified Hematopoietic: WBC greater than 3,500/mm3 Hemoglobin greater than&#xD;
        10 g/dL Platelet count greater than 150,000/mm3 Hepatic: Bilirubin less than 1.5 mg/dL GGT&#xD;
        less than upper limit of normal (ULN) AST less than ULN PT less than 14 seconds No&#xD;
        autoimmune hepatitis Renal: Creatinine less than 1.5 mg/dL OR Creatinine clearance greater&#xD;
        than 60 mL/min Cardiovascular: No New York Heart Association class III or IV cardiac&#xD;
        disease Pulmonary: No severe debilitating pulmonary disease Other: No active uncontrolled&#xD;
        infection or infection requiring IV antibiotic treatment No evidence of human antimouse&#xD;
        antibody No prior autoimmune disease No prior GI hemorrhage HIV negative Fertile patients&#xD;
        must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY: Biologic therapy: At least 2 months since prior packed red blood&#xD;
        cell transfusion No prior murine or human antibody therapy No prior murine protein No other&#xD;
        concurrent immunotherapy Chemotherapy: At least 4 weeks since prior chemotherapy and&#xD;
        recovered No concurrent chemotherapy Endocrine therapy: See Disease Characteristics&#xD;
        Concurrent gonadotropin releasing hormone analogs required for patients who have not&#xD;
        undergone surgical orchiectomy No other concurrent hormonal therapy Radiotherapy: See&#xD;
        Disease Characteristics At least 4 weeks since prior radiotherapy and recovered No prior&#xD;
        diagnostic scintigram (e.g., ProstaScint, Myoscint, or Oncoscint) No prior radiotherapy to&#xD;
        more than the sternum alone OR No primary radiotherapy to the prostate and one other site&#xD;
        OR No prior radiotherapy to more than 25% of the skeleton No prior treatment with strontium&#xD;
        chloride Sr 89 or Samarium Sm 153 lexidronam pentasodium No concurrent radiotherapy to&#xD;
        localized sites (e.g.,bone) used as indicator lesions Surgery: No concurrent surgery to&#xD;
        sole site of measurable disease Other: At least 4 weeks since investigational anticancer&#xD;
        therapeutic drugs and recovered No concurrent aspirin, nonsteroidal antiinflammitory&#xD;
        agents, anticoagulants, or other drugs that may induce or exacerbate a bleeding tendency&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Howard I. Scher, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>October 4, 2000</study_first_submitted>
  <study_first_submitted_qc>June 8, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 9, 2004</study_first_posted>
  <last_update_submitted>June 17, 2013</last_update_submitted>
  <last_update_submitted_qc>June 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 18, 2013</last_update_posted>
  <keyword>stage III prostate cancer</keyword>
  <keyword>stage IV prostate cancer</keyword>
  <keyword>recurrent prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antineoplastic Agents, Immunological</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

